ArticleMolecular and cellular biochemistry2026
Cancer-associated fibroblasts drive immune resistance in MSS colorectal cancer via the FAIM2-CES1-ER stress pathway.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Microsatellite-stable (MSS) colorectal cancer (CRC) shows limited responsiveness to immune checkpoint inhibitors, often in the context of a fibrotic and immunosuppressive tumor microenvironment. Cancer-associated fibroblasts (CAFs) are central to extracellular matrix (ECM) remodeling, yet the underlying regulatory mechanisms remain unclear. Here, we identify Fas apoptotic inhibitory molecule 2 (FAIM2) as a stromal regulator that is downregulated in MSS CRC and associated with immune infiltration and patient prognosis. Single-cell RNA sequencing localizes FAIM2 predominantly to CAFs, where it inversely correlates with collagen production. Functional studies in L-929 cells and primary CAFs show that FAIM2 overexpression suppresses endoplasmic reticulum (ER) stress signaling and reduces collagen I and matrix metalloproteinase 2 (MMP2) expression; these effects are attenuated by the ER stress inducer Tunicamycin. Conversely, FAIM2 knockdown enhances ER stress and collagen synthesis, which are mitigated by the ER stress inhibitor tauroursodeoxycholic acid (TUDCA). Mechanistically, carboxylesterase 1 (CES1) is identified as a downstream effector negatively regulated by FAIM2, mediating ER stress and ECM remodeling. In vivo, FAIM2 overexpression restrains tumor growth, reduces collagen deposition, and promotes tertiary lymphoid structure (TLS) formation, whereas CES1 co-overexpression counteracts these effects. Together, these findings reveal a potential FAIM2-CES1-ER stress axis in CAFs associated with ECM remodeling and immune contexture in MSS CRC, providing a rationale for future studies exploring its therapeutic potential in immunotherapy.
Indexed as
Identifiers
42742855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.